Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Tuberculous Meningitis

  • Author: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS; Chief Editor: Niranjan N Singh, MD, DM  more...
 
Updated: Dec 11, 2014
 

Background

Tuberculous meningitis (TBM) develops in 2 steps. Mycobacterium tuberculosis bacilli enter the host by droplet inhalation. Localized infection escalates within the lungs, with dissemination to the regional lymph nodes. In persons who develop TBM, bacilli seed to the meninges or brain parenchyma, resulting in the formation of small subpial or subependymal foci of metastatic caseous lesions, termed Rich foci.

The second step in the development of TBM is an increase in size of a Rich focus until it ruptures into the subarachnoid space. The location of the expanding tubercle (ie, Rich focus) determines the type of CNS involvement. Tubercles rupturing into the subarachnoid space cause meningitis. (See Pathophysiology.)

Currently, more than 2 billion people (ie, one third of the world’s population) are infected with tuberculosis (TB), of which approximately 10% will develop clinical disease. The incidence of central nervous system (CNS) TB is related to the prevalence of TB in the community, and it is still the most common type of chronic CNS infection in developing countries.

Despite great advances in immunology, microbiology, and drug development, TB remains among the great public health challenges. Poverty; lack of functioning public health infrastructure; lack of funding to support basic research aimed at developing new drugs, diagnostics, and vaccines; and the co-epidemic of HIV continue to fuel the ongoing epidemic of TB. (See Epidemiology.)

TBM is a very critical disease in terms of fatal outcome and permanent sequelae, requiring rapid diagnosis and treatment. Prediction of prognosis of TBM is difficult because of the protracted course, diversity of underlying pathological mechanisms, variation of host immunity, and virulence of M tuberculosis. Prognosis is related directly to the clinical stage at diagnosis. (See Prognosis.)

TBM may have an acute presentation. Sometimes it may present with cranial nerve deficits, or it may have a more indolent course involving headache, meningismus, and altered mental status. The prodrome is usually nonspecific, including headache, vomiting, photophobia, and fever. The duration of presenting symptoms may vary from 1 day to 9 months. (See Clinical Presentation.)

TBM continues to pose a diagnostic problem. A high index of clinical suspicion is absolutely essential. TBM should be a strong consideration when a patient presents with a clinical picture of meningoencephalitides, especially in high-risk groups. Diagnostic confusion often exists between TBM and other meningoencephalitides, in particular partially treated meningitis. TBM must be differentiated not only from other forms of acute and subacute meningitis but also from conditions such as viral infections and cerebral abscess. (See Diagnosis.)

The diagnosis of TBM cannot be made or excluded solely on the basis of clinical findings. Tuberculin testing is of limited value. Variable natural history and accompanying clinical features of TBM hinder the diagnosis. Spinal tap carries some risk of herniation of the medulla in any instance when intracranial pressure (ICP) is increased (eg, TBM), but if meningitis is suspected, the procedure must be performed regardless of the risk. CNS imaging modalities lack specificity but help in monitoring complications that require neurosurgery. (See Workup.)

Prompt treatment is essential; death may occur as a result of missed diagnoses and delayed treatment. Antimicrobial therapy is best started with isoniazid, rifampin, pyrazinamide; addition of a fourth drug is left to local choice. The optimal duration of antimicrobial therapy is unclear. The benefits of adjuvant corticosteroids remain in doubt: their use in adults is controversial, though they may be indicated in the presence of increased ICP, altered consciousness, focal neurological findings, spinal block, and tuberculous encephalopathy.

In patients with evidence of obstructive hydrocephalus and neurological deterioration who are undergoing treatment for TBM, placement of a ventricular drain or ventriculoperitoneal or ventriculoatrial shunt should not be delayed. Prompt shunting improves outcome, particularly in patients presenting with minimal neurological deficit. (See Treatment and Management.)

New research avenues include research into vaccine design, mechanisms of drug resistance, and virulence determinants. Rapid sensitivity testing using bacteriophages considers the problem of drug resistance.

Go to Meningitis, Meningococcal Meningitis, Staphylococcal Meningitis, Haemophilus Meningitis, Viral Meningitis, and Aseptic Meningitis for more complete information on these topics.

Next

Pathophysiology

Many of the symptoms, signs, and sequelae of tuberculous meningitis (TBM) are the result of an immunologically directed inflammatory reaction to the infection. TBM develops in 2 steps. Mycobacterium tuberculosis bacilli enter the host by droplet inhalation, the initial point of infection being the alveolar macrophages. Localized infection escalates within the lungs, with dissemination to the regional lymph nodes to produce the primary complex. During this stage, a short but significant bacteremia is present that can seed tubercle bacilli to other organs.

In persons who develop TBM, bacilli seed to the meninges or brain parenchyma, resulting in the formation of small subpial or subependymal foci of metastatic caseous lesions. These are termed Rich foci, after the original pathologic studies of Rich and McCordick.[1] Tuberculous pneumonia develops with heavier and more prolonged tuberculous bacteremia. Dissemination to the central nervous system (CNS) is more likely, particularly if miliary tuberculosis (TB) develops.

The second step in the development of TBM is an increase in size of a Rich focus until it ruptures into the subarachnoid space. The location of the expanding tubercle (ie, Rich focus) determines the type of CNS involvement. Tubercles rupturing into the subarachnoid space cause meningitis. Those deeper in the brain or spinal cord parenchyma cause tuberculomas or abscesses. While an abscess or hematoma can rupture into the ventricle, a Rich focus does not.

A thick gelatinous exudate infiltrates the cortical or meningeal blood vessels, producing inflammation, obstruction, or infarction. Basal meningitis accounts for the frequent dysfunction of cranial nerves (CNs) III, VI, and VII, eventually leading to obstructive hydrocephalus from obstruction of basilar cisterns. Subsequent neurological pathology is produced by 3 general processes: adhesion formation, obliterative vasculitis, and encephalitis or myelitis.

Formation of tuberculomas

Tuberculomas are conglomerate caseous foci within the substance of the brain, as shown in the image below. Centrally located, active lesions may reach considerable size without producing meningitis.[1] Under conditions of poor host resistance, this process may result in focal areas of cerebritis or frank abscess formation, but the usual course is coalescence of caseous foci and fibrous encapsulation (ie, tuberculoma).

Tuberculoma is the round gray mass in the left cor Tuberculoma is the round gray mass in the left corpus callosum. The red meninges on the right are consistent with irritation and probable meningeal reaction to tuberculosis. Courtesy of Robert Schelper, MD, Associate Professor of Pathology, State University of New York Upstate Medical University.

Tuberculomas may coalesce together or grow in size, even during ongoing antitubercular therapy[2] ; this process may have an immunological basis.[3] Tuberculomas can also involve the adjacent intracranial trunk artery, largely causing vasculitis.[4] Probable embolic spread of tuberculomas in the brain in multidrug resistant TBM has been reported.[5]

Spinal involvement

In the tuberculous process, the spinal meninges may be involved, owing to the spread of infection from intracranial meningitis, primary spinal meningitis in isolation as a result of a tuberculous focus on the surface of the cord rupturing into the subarachnoid space, or transdural extension of infection from caries of the spine.

Pathologically, a gross granulomatous exudate fills the subarachnoid space and extends over several segments. Vasculitis involving arteries and veins occurs, sometimes resulting in ischemic spinal cord infarction.

The earliest lesion in the vertebra is invariably due to hematogenous spread, often involving the body of the vertebra near an intervertebral disk. The intervertebral disk is almost always involved with the spread of the disease to the adjacent vertebra and eventually along the anterior or posterior longitudinal ligaments or through the end plate. Soon, a cold abscess develops, either as a paraspinal abscess in the dorsal and lumbar regions or as a retropharyngeal abscess in the cervical region.

As the disease progresses, increasing decalcification and erosion result in progressive collapse of the bone and destruction of intervertebral disks, involving as many as 3-10 vertebrae in one lesion, resulting in kyphosis. The abscess may rupture intraspinally, resulting in primary spinal meningitis, hyperplastic peripachymeningitis, intraspinal abscess, or tuberculoma.

Pathological effects on other organs

Papilledema is the most common visual effect of TBM. In children, papilledema may progress to primary optic atrophy and blindness resulting from direct involvement of the optic nerves and chiasma by basal exudates (ie, opticochiasmatic arachnoiditis). In adults, papilledema may progress more commonly to secondary optic atrophy, provided the patient survives long enough. Other causes of visual impairment include chorioretinitis, optic neuritis, internuclear ophthalmoplegia, and, occasionally, an abrupt onset of painful ophthalmoplegia.

Ocular involvement is rare in TB. When it occurs, the typical lesion is often a choroidal granuloma. Baha Ali and coworkers describe 3 cases of choroidal TB associated with 3 different clinical situations, including tuberculous meningitis, multifocal TB, and military TB with HIV.[6]

CN VI is affected most frequently by TBM, followed by CNs III, IV, VII, and, less commonly, CNs II, VIII, X, XI, and XII.[7]

Sudden onset of focal neurological deficits, including monoplegia, hemiplegia, aphasia, and tetraparesis, has been reported. Although these could be postictal phenomena, they mostly are due to vasculitic changes resulting in ischemia. While some of these could be the result of proliferative arachnoiditis or hydrocephalus, vasculitis still appears to be the leading cause.

Vasculitis with resultant thrombosis and hemorrhagic infarction may develop in vessels that traverse the basilar or spinal exudate or lie within the brain substance. Mycobacterium also may invade the adventitia directly and initiate the process of vasculitis.

An early neutrophilic reaction is followed by infiltration of lymphocytes, plasma cells, and macrophages, leading to progressive destruction of the adventitia, disruption of elastic fibers, and, finally, intimal destruction. Eventually, fibrinoid degeneration within small arteries and veins produces aneurysms, multiple thrombi, and focal hemorrhages, alone or in combination.[8]

Tremor is the most common movement disorder seen in the course of TBM. In a smaller percentage of patients, abnormal movements, including choreoathetosis and hemiballismus, have been observed, more so in children than in adults. In addition, myoclonus and cerebellar dysfunction have been observed. Deep vascular lesions are more common among patients with movement disorders.

Previous
Next

Etiology

The causative organism is Mycobacterium tuberculosis. Various risk factors have been identified.

The first description of TBM is credited to Robert Whytt, on the basis of his 1768 monograph, Observations of Dropsy in the Brain. TBM first was described as a distinct pathological entity in 1836, and Robert Koch demonstrated that TB was caused by M tuberculosis in 1882. M tuberculosis is an aerobic gram-positive rod that stains poorly with hematoxylin and eosin (H&E) because of its thick cell wall that contains lipids, peptidoglycans, and arabinomannans. The high lipid content in its wall makes the cells impervious to Gram staining. However, Ziehl-Neelsen stain forms a complex in the cell wall that prevents decolorization by acid or alcohol, and the bacilli are stained a bright red, which stands out clearly against a blue background.

Mycobacteria vary in appearance from spherical to short filaments, which may be branched. Although they appear as short to moderately long rods, they can be curved and frequently are seen in clumps. Individual bacilli generally are 0.5-1 µm in diameter and 1.5-10 µm long. They are nonmotile and do not form spores.

One of the distinct characteristics of mycobacteria is their ability to retain dyes within the bacilli that usually are removed from other microorganisms by alcohols and dilute solutions of strong mineral acids such as hydrochloric acid. This ability is attributed to a waxlike layer composed of long-chain fatty acids, the mycolic acids, in their cell wall. As a result, mycobacteria are termed acid-fast bacilli.

The mechanisms by which neurovirulence may occur are unknown.

Risk factors

Human migration plays a large role in the epidemiology of TB. Massive human displacement during wars and famines has resulted in increased case rates of TB and an altered geographic distribution. With the advent of air travel, TB has a global presence. In the United States, the prevalence of TB, mostly in foreign-born persons, has steadily increased.

Once infected with M tuberculosis, HIV co-infection is the strongest risk factor for progression to active TB; the risk has been estimated to be as great as 10% per year, compared with 5-10% lifetime risk among persons with TB but not HIV infection. Although patients who have HIV infection and TB are at increased risk for TBM, the clinical features and outcomes of TB do not seem to be altered by HIV. Go to HIV-1 Associated CNS Conditions - Meningitis for more complete information on this topic.

Patients infected with HIV, especially those with AIDS, are at very high risk of developing active TB when exposed to a person with infectious drug-susceptible or drug-resistant TB. They have a higher incidence of drug-resistant TB, in part due to Mycobacterium avium-intracellulare, and have worse outcomes.

Other predisposing factors for the development of active TB include malnutrition, alcoholism, substance abuse, diabetes mellitus, corticosteroid use, malignancy, and head trauma. Homeless persons, people in correctional facilities, and residents of long-term care facilities also have a higher risk of developing active TB compared with the general population.

Previous
Next

Epidemiology

TB is the seventh leading cause of death and disability worldwide. In 1997, TBM was the fifth most common form of extrapulmonary TB. TBM accounted for 5.2% (186) of all cases of exclusively extrapulmonary disease and 0.7% of all reported cases of TB.

United States statistics

Between 1969 and 1973, TBM accounted for approximately 4.5% of the total extrapulmonary TB morbidity in the United States. Between 1975 and 1990, 3,083 cases of TBM were reported by the US Centers for Disease Control and Prevention (CDC), an average of 193 cases per year, accounting for 4.7% of total extrapulmonary TB cases during that 16-year period.

In 1990, however, 284 cases of TBM were reported, constituting 6.2% of the morbidity attributed to extrapulmonary TB. This increase in TBM was most likely due to increasing CNS TB among patients with HIV/AIDS and to the increasing incidence of TB among infants, children, and young adults of minority populations.

Data suggest that TBM accounts for 2.1% of pediatric cases and 9.1% of extrapulmonary TB cases.[9] TB accounts for approximately 0.04% of all cases of chronic suppurative otitis media.[10] The Tuberculosis: Advocacy Report released by the World Health organization (WHO) in 2003 suggests the persistence of TB otitis, as well as possibly an increase in the incidence of TB otitis.[11] Tuberculomas account for 10-30% of intracranial masses in TB-endemic areas.

International statistics

The WHO estimates that one third of the world’s population is infected by M tuberculosis. The WHO’s 2003 publication Tuberculosis: Advocacy Report stated that 8 million new cases of TB are reported annually and 2 million deaths occur each year.[11] An estimated 8.8 million new TB cases were recorded in 2005 worldwide, 7.4 million in Asia and sub-Saharan Africa. A total of 1.6 million people died from TB, including 195,000 patients infected with HIV.[12]

In 2005, the TB incidence rate was stable or in decline in all 6 WHO regions. However, the total number of new TB cases was still rising slowly; the case-load continues to grow in the African, eastern Mediterranean, and Southeast Asia regions.[13] In many areas of Africa and Asia, the annual incidence of TB infection for all ages is approximately 2%, which would yield an estimated 200 cases of TB per 10,000 population per year. Approximately 15-20% of these cases occur in children younger than 15 years.

The worldwide prevalence of TB in children is difficult to assess because data are scarce and poorly organized. The available reports grossly underestimate the true incidence. Lack of surveillance testing in most areas of the world restricts the ability to assess the prevalence of the disease. The developing world has 1.3 million cases of TB and 40,000 TB-related deaths annually among children younger than 15 years. In the developing world, 10-20% of persons who die of TB are children. TBM complicates approximately 1 of every 300 untreated primary TB infections.

Age distribution for TBM

Prior to the appearance of HIV, the most important determinant for the development of TBM was age. Data published in 2000 revealed that the risk increased with age across racial and ethnic groups.

In populations with a low prevalence of TB, most cases of TBM occur in adults. In the United States in 1996, case rates were low in infancy and decreased somewhat during early childhood. After the age of puberty, they showed a steady increase with age.

In general, however, TBM is more common in children than in adults, especially in the first 5 years of life. In fact, children aged 0-5 years are affected more commonly with TBM than any other age group. TBM is uncommon, however, in children younger than 6 months and almost unheard of in infants younger than 3 months because the causative pathological sequence takes at least 3 months to develop.

Children aged 5-14 years often have been referred to as the favored age because they have lower rates of TB than any other age group.

Younger children are more likely to develop meningeal, disseminated, or lymphatic TB, whereas adolescents more frequently present with pleural, genitourinary, or peritoneal disease.

Childhood TB has a limited influence on the immediate epidemiology of the disease because children rarely are a source of infection to others.

Sex distribution for TBM

Among persons younger than 20 years, TB infection rates are similar for both sexes; the lowest rates are observed in children aged 5-14 years. During adulthood, TB infection rates are consistently higher for men than for women; the male-to-female ratio is approximately 2:1.

Prevalence of TBM by race

Case rates in whites are lowest at all age groups, and rates in Asians and Pacific Islanders are the highest, particularly among adults. Rates among Blacks, Hispanics, and Native Americans/Alaskan Natives are intermediate. Black men have appreciably higher rates than Hispanic and Native American/Alaskan Native men, except in the oldest age group.

In 2000, approximately 75% of all reported TB cases occurred in racial and ethnic minorities, including 32% in non-Hispanic blacks, 23% in Hispanics, 21% in Asians and Pacific Islanders, and 1% in Native Americans and Alaskan Natives. Approximately 22% of all reported cases occurred in non-Hispanic whites.

Several important factors likely contribute to the disproportionate burden of TB in minorities. In foreign-born persons from countries where TB is common, active TB disease may result from infection acquired in the country of origin. Approximately 95% of cases in the Asian/Pacific Islander group occurred in foreign-born persons, compared with 70% of cases in Hispanics and 20% of cases in non-Hispanic blacks.

In racial and ethnic minorities, unequal distribution of TB risk factors, such as HIV infection, also may contribute to an increased exposure to TB or to the risk of developing active TB once infected with M tuberculosis. However, much of the increased risk of TB in minorities has been linked to lower socioeconomic status and the effects of crowding, particularly among US-born persons.

Previous
Next

Prognosis

TBM is a very critical disease in terms of fatal outcome and permanent sequelae, requiring rapid diagnosis and treatment. The number of deaths due to TB has decreased dramatically since 1953. In 1953, 19,707 deaths from TB were reported in the United States, for a rate of 12.4 deaths per 100,000 population. In 1997, 1,166 deaths were reported, for a rate of 0.4 deaths per 100,000 population.

The number of TB deaths and the TB death rate increased slightly during a recent TB resurgence, reaching a high in 1989 of 1,970 deaths and a rate of 0.8 deaths per 100,000 population before decreasing again.

Patients with TBM continue to do poorly in the long term, in spite of optimal anti-tuberculous therapy. While increasing age and co-infection with HIV might offer some explanation, they do not explain the whole picture.[14]

Prediction of outcome

Prediction of prognosis of TBM is difficult because of the protracted course, diversity of underlying pathological mechanisms, variation of host immunity, and virulence of M tuberculosis. Prognosis is related directly to the clinical stage at diagnosis.

Initially, only clinical indices were used for predicting the outcome, such as level of consciousness, stage of meningitis, bacillus Calmette-Guérin (BCG) vaccination status, cerebrospinal fluid (CSF) findings, and evidence of raised intracranial pressure (ICP). After computed tomography (CT) scanning became available, radiological findings, such as hydrocephalus, infarction, severity of exudate, and tuberculoma, also were considered for predicting the prognosis of TBM.

A recent study that looked at clinical parameters, laboratory studies, and CT scan features in 49 adults and children with TBM used a multivariate logistic regression model to show that the most significant variables for predicting outcome in TBM were age, stage of disease, focal weakness, CN palsy, and hydrocephalus.[15] Children with advanced disease with neurological complications have poor outcomes.

The occurrence of syndrome of inappropriate diuretic hormone secretion (SIADH) is common and is also linked to a poor prognosis.

Sinha et al report that they found visual impediment a predictable prelude to severe disability or death.[16] It was often the result of optochiasmatic arachnoiditis or optochiasmal tuberculoma.

Few studies on neurophysiological changes are reported in TBM. EEG has been reported to be useful in assessing the gravity of lesions and was reported recently to help in prediction of outcome. Motor evoked potentials and somatosensory evoked potentials also have been reported recently to predict a 3-month outcome of TBM. Misra et al found that focal weakness, Glasgow Coma Scale score, and somatosensory evoked potential findings were the best predictors of 6-month outcome in patients with TBM.[17]

Hydrocephalus was the only factor shown to be significant in predisposing patients with TBM who had positive culture results to a poorer outcome. A trend toward a poorer prognosis was also seen in those with advanced stages of the disease.

While clinical features in children with TBM who were also infected with HIV and those who were not co-infected with HIV were not markedly different, abnormal radiological findings were more common in the HIV-infected group and outcomes were considerably worse. Coexisting HIV encephalopathy and diminished immune competence undoubtedly contributed to the more severe clinical and neuroradiological features.

Kumar et al reported that children with TBM who have been vaccinated with BCG appear to maintain better mentation and have superior outcomes. They believe this may be explained, in part, by the better immune response to infection, as is reflected in the higher CSF cell counts in their patient group.[18]

Previous
Next

Patient Education

Health education efforts must be directed at the patients to make them more informed and aware of all aspects of the disease and its treatment. Patients must be informed of the basic rules to prevent spreading the infection to others in the family or the community.

Whereas one end of the spectrum of educational efforts is directed toward the health-related behavior of the general public, the other end should be directed toward gaining the support of those who influence health policies and funding of governments and institutions. To achieve this, information, education, and communication (IEC) campaigns should be designed to act as an intermediary between the 2 groups. This strategy includes social marketing, health promotion, social mobilization, and advocacy programs.

We do have a successful model of smallpox eradication; if all interested and influential partners come together in a concerted effort, we could and would eliminate TB.

For patient education resources, see the Bacterial and Viral Infections Center, Brain and Nervous System Center, and Procedures Center, as well as Tuberculosis, Meningitis in Adults, Meningitis in Children, and Spinal Tap.

Previous
 
 
Contributor Information and Disclosures
Author

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS is a member of the following medical societies: American College of International Physicians, American Heart Association, American Stroke Association, American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners Institute, National Association of Managed Care Physicians, American College of Physicians, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, Royal Society of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Niranjan N Singh, MD, DM Associate Professor of Neurology, University of Missouri-Columbia School of Medicine

Niranjan N Singh, MD, DM is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Headache Society

Disclosure: Nothing to disclose.

Acknowledgements

Pieter R Kark, MD, MA, FAAN, FACP Instructor in Palliative Care, The Lifetime Healthcare Companies

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Florian P Thomas, MD, MA, PhD, Drmed Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Director, Neuropathy Association Center of Excellence, Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University School of Medicine

Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Paraplegia Society, Consortium of Multiple Sclerosis Centers, and National Multiple Sclerosis Society

Disclosure: Nothing to disclose.

Frederick M Vincent Sr, MD Clinical Professor, Department of Neurology and Ophthalmology, Michigan State University Colleges of Human and Osteopathic Medicine

Frederick M Vincent Sr, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American College of Forensic Examiners, American College of Legal Medicine, American College of Physicians, and Michigan State Medical Society

Disclosure: Nothing to disclose.

References
  1. Rich AR, McCordick HA. The pathogenesis of tuberculous meningitis. Bulletin of John Hopkins Hospital. 1933. 52:5-37.

  2. Nicolls DJ, King M, Holland D, Bala J, del Rio C. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect Dis. 2005 Dec. 5(12):795-801. [Medline].

  3. Hejazi N, Hassler W. Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy: literature review and a case report. Infection. 1997 Jul-Aug. 25(4):233-9. [Medline].

  4. Blanco Garcia FJ, Sanchez Blas M, Freire Gonzalez M. Histopathologic features of cerebral vasculitis associated with mycobacterium tuberculosis. Arthritis Rheum. 1999 Feb. 42(2):383. [Medline].

  5. Kohli A, Kapoor R. Neurological picture. Embolic spread of tuberculomas in the brain in multidrug resistant tubercular meningitis. J Neurol Neurosurg Psychiatry. 2008 Feb. 79(2):198. [Medline].

  6. Geissl G. [Tuberculosis or occult neoplasm?]. MMW Munch Med Wochenschr. 1979 Apr 27. 121(17):26. [Medline].

  7. Zuger A, Lowy FD. Tuberculosis. Scheld WM, Whitley RJ, Durack DT, eds. Infections of the Central Nervous System. 2nd ed. Philadelphia: Lippincott-Raven; 1997. 417-443.

  8. Dastur DK, Manghani DK, Udani PM. Pathology and pathogenetic mechanisms in neurotuberculosis. Radiol Clin North Am. 1995 Jul. 33(4):733-52. [Medline].

  9. Nelson LJ, Schneider E, Wells CD, Moore M. Epidemiology of childhood tuberculosis in the United States, 1993-2001: the need for continued vigilance. Pediatrics. 2004 Aug. 114(2):333-41. [Medline].

  10. Jeang MK, Fletcher EC. Tuberculous otitis media. JAMA. 1983 Apr 22-29. 249(16):2231-2. [Medline].

  11. World Health Organization. Tuberculosis: Advocacy Report. World Health Organization. Available at http://www.who.int/tb/publications/advocacy_report_2003/en/index.html. Accessed: 2003.

  12. Tabbara KF. Tuberculosis. Curr Opin Ophthalmol. 2007 Nov. 18(6):493-501. [Medline].

  13. World Health Organization. Tuberculosis. World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed: 12/4/08.

  14. Shaw JE, Pasipanodya JG, Gumbo T. Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore). 2010 May. 89(3):189-95. [Medline].

  15. Moghtaderi A, Alavi-Naini R, Rashki S. Cranial nerve palsy as a factor to differentiate tuberculous meningitis from acute bacterial meningitis. Acta Med Iran. 2013 Mar 16. 51(2):113-8. [Medline].

  16. Sinha MK, Garg RK, Anuradha Hk, Agarwal A, Singh MK, Verma R, et al. Vision impairment in tuberculous meningitis: predictors and prognosis. J Neurol Sci. 2010 Mar 15. 290(1-2):27-32. [Medline].

  17. Misra UK, Kalita J, Srivastava M, et al. Prognosis of tuberculous meningitis: a multivariate analysis. J Neurol Sci. 1996 Apr. 137(1):57-61. [Medline].

  18. Kumar R, Dwivedi A, Kumar P, Kohli N. Tuberculous meningitis in BCG vaccinated and unvaccinated children. J Neurol Neurosurg Psychiatry. 2005 Nov. 76(11):1550-4. [Medline].

  19. Walker V, Selby G, Wacogne I. Does neonatal BCG vaccination protect against tuberculous meningitis?. Arch Dis Child. 2006 Sep. 91(9):789-91. [Medline].

  20. Biswas J, Madhavan HN, Gopal L, Badrinath SS. Intraocular tuberculosis. Clinicopathologic study of five cases. Retina. 1995. 15(6):461-8. [Medline].

  21. Alarcón F, Moreira J, Rivera J, Salinas R, Dueñas G, Van den Ende J. Tuberculous meningitis: do modern diagnostic tools offer better prognosis prediction?. Indian J Tuberc. 2013 Jan. 60(1):5-14. [Medline].

  22. Dendane T, Madani N, Zekraoui A, Belayachi J, Abidi K, Zeggwagh AA, et al. A simple diagnostic aid for tuberculous meningitis in adults in Morocco by use of clinical and laboratory features. Int J Infect Dis. 2013 Mar 24. [Medline].

  23. Ho J, Marais BJ, Gilbert GL, Ralph AP. Diagnosing tuberculous meningitis - have we made any progress?. Trop Med Int Health. 2013 Mar 25. [Medline].

  24. Thwaites GE. Advances in the diagnosis and treatment of tuberculous meningitis. Curr Opin Neurol. 2013 Mar 12. [Medline].

  25. Sastry AS, Bhat K S, Kumudavathi. The Diagnostic Utility of Bact/ALERT and Nested PCR in the Diagnosis of Tuberculous Meningitis. J Clin Diagn Res. 2013 Jan. 7(1):74-8. [Medline]. [Full Text].

  26. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) an. Am J Respir Crit Care Med. 2000 Apr. 161(4 Pt 2):S221-47. [Medline].

  27. Sumi MG, Annamma M, Sarada C, Radhakrishnan VV. Rapid diagnosis of tuberculous meningitis by a dot-immunobinding assay. Acta Neurol Scand. 2000 Jan. 101(1):61-4. [Medline].

  28. Weisberg LA. Granulomatous diseases of the CNS as demonstrated by computerized tomography. Comput Radiol. 1984 Sep-Oct. 8(5):309-17. [Medline].

  29. Srikanth SG, Taly AB, Nagarajan K, Jayakumar PN, Patil S. Clinicoradiological features of tuberculous meningitis in patients over 50 years of age. J Neurol Neurosurg Psychiatry. 2007 May. 78(5):536-8. [Medline].

  30. Yadav A, Chaudhary C, Keshavan AH, Agarwal A, Verma S, Prasad KN, et al. Correlation of CSF proinflammatory cytokines with MRI in tuberculous meningitis. Acad Radiol. 2010 Feb. 17(2):194-200. [Medline].

  31. Janvier F, Servonnet A, Delacour H, Fontan E, Ceppa F, Burnat P. [Value of assaying adenosine deaminase level in patients with neuromeningeal tuberculosis]. Med Trop (Mars). 2010 Feb. 70(1):88-93. [Medline].

  32. Stevens DL, Everett ED. Sequential computerized axial tomography in tuberculous meningitis. JAMA. 1978 Feb 13. 239(7):642. [Medline].

  33. Figaji AA, Sandler SI, Fieggen AG, Le Roux PD, Peter JC, Argent AC. Continuous monitoring and intervention for cerebral ischemia in tuberculous meningitis. Pediatr Crit Care Med. 2008 Jul. 9(4):e25-30. [Medline].

  34. Schoeman J, Mansvelt E, Springer P, van Rensburg AJ, Carlini S, Fourie E. Coagulant and fibrinolytic status in tuberculous meningitis. Pediatr Infect Dis J. 2007 May. 26(5):428-31. [Medline].

  35. Gourie-Devi M, Satish P. Hyaluronidase as an adjuvant in the treatment of cranial arachnoiditis (hydrocephalus and optochiasmatic arachnoiditis) complicating tuberculous meningitis. Acta Neurol Scand. 1980 Dec. 62(6):368-81. [Medline].

  36. Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, et al. Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS. 2007 Oct 1. 21(15):2043-50. [Medline].

  37. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997 Feb. 99(2):226-31. [Medline].

  38. Wasay M. Central nervous system tuberculosis and paradoxical response. South Med J. 2006 Apr. 99(4):331-2. [Medline].

  39. Wasay M, Kheleani BA, Moolani MK, et al. Brain CT and MRI findings in 100 consecutive patients with intracranial tuberculoma. J Neuroimaging. 2003 Jul. 13(3):240-7. [Medline].

  40. Gupta M, Bajaj BK, Khwaja G. Paradoxical response in patients with CNS tuberculosis. J Assoc Physicians India. 2003 Mar. 51:257-60. [Medline].

  41. Shelburne SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev. 2003 Apr-Jun. 5(2):67-79. [Medline].

  42. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004 Aug. 59(8):704-7. [Medline].

  43. Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003 Oct. 22(10):597-602. [Medline].

  44. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010 Mar 5. 59(8):224-9. [Medline].

 
Previous
Next
 
Tuberculoma is the round gray mass in the left corpus callosum. The red meninges on the right are consistent with irritation and probable meningeal reaction to tuberculosis. Courtesy of Robert Schelper, MD, Associate Professor of Pathology, State University of New York Upstate Medical University.
MRI of the brain in a patient with 8 CD4 cells/mL. The patient's history includes previous interstitial pneumonia, pericarditis, adnexitis, and a positive result on the Mantoux test. His recent history includes fever, headache, strabismus, diplopia, and cough. Laboratory studies revealed hyponatremia. Liquoral findings strongly suggested a diagnosis of tuberculous meningitis, and culture results were positive for Mycobacterium tuberculosis. The MRI shows the presence, in and over the sellar seat, with parasellar left extension, of tissue with irregular margins, marked inhomogeneous enhancement, and compression of optic chiasm and of the third ventricle. Presence of nodular areas with marked enhancement of basal cisterns is an expression of leptomeningeal involvement. This patient died after 2 months of inadequate antituberculosis therapy (ie, poor compliance). Courtesy of Salvatore Marra, AIDS Imaging (http://members.xoom.it/Aidsimaging).
Fluorochrome for tuberculosis. Fluorescent staining procedures are used with auramine O or auramine-rhodamine as the primary fluorochrome dye. After decolorization with an acid-alcohol preparation, the smear is counterstained with acridine orange or thiazine red and scanned at a lower magnification with a 25X dry objective fluorescent microscope. Acid-fast bacilli appear as yellow-green fluorescent thin rods against a dark background. Courtesy of Robert Schelper, MD, Associate Professor of Pathology, State University of New York Upstate Medical University.
Hematoxylin and eosin stain showing caseation in tuberculosis. Courtesy of Robert Schelper, MD, Associate Professor of Pathology, State University of New York Upstate Medical University.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.